THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
October 11, 2017 08:19 ET | Abeona Therapeutics Inc
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
October 06, 2017 08:25 ET | Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
September 28, 2017 08:32 ET | Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
August 29, 2017 09:05 ET | Abeona Therapeutics Inc
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapyBreakthrough Therapy designation enables priority review and expedites approval processEB-101 has demonstrated...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
August 17, 2017 09:15 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer
July 25, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, July 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
July 18, 2017 08:05 ET | Abeona Therapeutics Inc
Pivotal Phase 3 clinical trial is planned to commence in early 2018 EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
June 29, 2017 08:15 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
June 02, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 02, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 30, 2017 08:05 ET | Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...